Pricing Log in Create free account
Friday 6 November 2026 Export VRDN’s income statement to Excel — free account

Viridian Therapeutics, Inc.

VRDN Healthcare Biotechnology

Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.

Revenue
−63.5%
EPS
−5.00%
Free cash flow
−9.92%
Total debt
+1,064.9%

Quarter to September 2026, against a year earlier

28.81 0.26 +0.91%
Market cap
$3.2B
P/E
0.0×
Fwd P/E
−6.2×
Dividend yield
—
F-score
3/9
Altman Z
6.69
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Viridian Therapeutics, Inc. (VRDN) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Viridian Therapeutics, Inc. (VRDN) trades at a EV/Sales of 91.0×. Over the past ten years it has ranged from −37.3× (March 2021) to 4,002× (September 2025); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 25.7× (98.72%)
FY2024 2,004× 15.68%
FY2023 1,732× 519.88%
FY2022 279× 1,984.96%
FY2021 13.4× —
FY2020 −35.6× —
FY2019 −0.8× —
FY2018 4.4× (89.09%)
FY2017 40.7× —
FY2016 −4.6× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 57.7× 227.80%
Jun 2026 17.6× (3.76%)
Mar 2026 18.3× (28.97%)
Dec 2025 25.7× 39.74%
42 more quarters

Against its own ten years

Low −37.3× High 4,002×
Ten-year median 14.6×
Current reading's percentile 59

EV/Sales against peers

Company EV/Sales
VKTX Viking Therapeutics, Inc. compare n/m
TLX Telix Pharmaceuticals Limited compare n/m
CELC Celcuity, Inc. compare n/m
DYN Dyne Therapeutics, Inc. compare n/m
ELVN Enliven Therapeutics, Inc. compare n/m
TARS Tarsus Pharmaceuticals, Inc. compare 4.2×
IDYA IDEAYA Biosciences, Inc. compare 63.7×
VRDN Viridian Therapeutics, Inc. 91.0×
DNLI Denali Therapeutics Inc. compare 143×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on VRDN